Gastroesophageal reflux disease

Current Opinion in Gastroenterology

Volumn 15, Issue 4, 1999, Pages 333-338

  Falk, Gary W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE;

ANTIREFLUX OPERATION; ARTICLE; ASTHMA; CARDIOTOXICITY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HOARSENESS; HUMAN; LAPAROSCOPIC SURGERY; LARYNGITIS; LOWER ESOPHAGUS SPHINCTER; MUSCLE RELAXATION; POSTOPERATIVE COMPLICATION; STOMACH FUNDOPLICATION;

EID: 0032794875     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199907000-00011     Document Type: Article

References (34)

1. 1 Ho KY, Kang JY, Seow A: Prevalence of gastrointestinal symptoms in a multiracial Asian population with particular reference to reflux-type symptoms. Am J Gastroenterol 1998, 93:1816-1822.
2. 2 Triadafilopoulos G, Sharma R: Features of symptomatic gastroesophageal reflux disease in elderly patients. Am J Gastroenterol 1997, 92:2007-2011.
3. 3 Zimmerman J, Shohat V, Tsvang E, Arnon R, Safadi R, Wengrower D: Esophagitis is a major cause of upper gastrointestinal hemorrhage in the elderly. Scand J Gastroenterol 1997, 32:906-909.
4. 4 Plaisier PW, van Buuren HR, Bruining HA: An analysis of upper GI endoscopy done for patients in surgical intensive care: high incidence of, and morbidity from reflux oesophagitis. Eur J Surg 1997, 163:903-907.
5. 5 Paterson WG: Role of mast cell-derived mediators in acid-induced shortening of the esophagus. Am J Physiol 1998, 274:G385-G388. This study examined the effect of mast cell mediators on acid-induced esophageal shortening in an opossum model. Acid perfusion induced esophageal shortening, which was reversed when the animals were infused with mast cell-stabilizing agents. This study suggests that mast cell mediators are involved in acid-induced esophageal shortening.
6. 6 Penagini R, Hebbard G, Horowitz M, Dent J, Bermingham H, Jones K, Holloway RH: Motor function of the proximal stomach and visceral perception in gastro-oesophageal reflux disease. Gut 1998, 42:251-257. Transient lower esophageal sphincter relaxation is the major mechanism of gastroesophageal reflux. One stimulus for TLESR is gastric distention. This study examined proximal gastric motor function in nine GERD patients and nine controls. Proximal gastric tone was lower postprandially in the reflux patients than in the controls, and retention of a test meal in the proximal stomach was greater in patients than controls. These findings suggest that proximal gastric motor abnormalities may contribute to the increase in TLESRs in GERD.
7. 7 Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE: Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998, 115:1374-1380. Nitric oxide is an inhibitory neurotransmitter. Its role in TLESR induced by gastric distention was studied in a double-blind study of placebo versus the nitric oxide synthase inhibitor L-NMMA or in eight healthy volunteers. Gastric distention increased TLESRs during placebo infusion, whereas L-NMMA inhibited this increase in TLESR. These findings suggest that nitric oxide is involved in the triggering of TLESR.
8. 8 Lidums I, Checklin H, Mittal RK, Holloway RH: Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gut 1998, 43:12-16. The role of cholinergic pathways in TLESR was studied in 15 GERD patients by infusing atropine or saline in a randomized fashion for 60 minutes. Atropine completely inhibited TLESRs, demonstrating the importance of cholinergic pathways in TLESR.
9. 9 Trudgill NJ, Smith LF, Kershaw J, Riley SA: Impact of smoking cessation on salivary function in healthy volunteers. Scand J Gastroenterol 1998, 33:568-571.
10. 10 Penagini R, Mangano M, Bianchi PA: Effect of increasing the fat content but not the energy load of a meal on gastro-oesophageal reflux and lower esophageal sphincter motor function. Gut 1998, 42:330-333.
11. 11 Varanasi RV, Fantry GT, Wilson KT: Decreased prevalence of H. pylori infection in gastroesophageal reflux disease. Helicobacter 1998, 3:188-194.
12. + H. pylori strains decreased in patients with more severe complications of GERD: GERD 36.7% (nonerosive vs erosive GERD, 41.2% vs 30.8%, respectively), Barrett's esophagus (13.3%), and Barrett's with adenocarcinoma/dysplasia (0%).
13. 13 Csendes A, Smok G, Burdiles P, Sagastume H, Rojas J, Puente G, et al.: Carditis: an objective histologic marker for pathologic gastroesophageal reflux disease. Dis Esophagus 1998, 11:101-105.
14. 14 Goldblum JR, Vicari JJ, Falk GW, Rice TW, Peek RM, Easley K, Richter JE: Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998, 114:633-639. Carditis has been proposed to be a marker of GERD. However, this study found no difference in the prevalence of H. pylori infection or cardia inflammation between GERD patients and a control population. All 11 controls and 22 of 23 GERD patients (96%) with carditis had H. pylori infection. Carditis in this study was associated with H. pylori pangastritis and not with GERD.
15. 15 Chen YY, Antonioli DA, Spechler SJ, Zeroogian JM, Goyal RK, Wang HH: Gastroesophageal reflux disease versus Helicobacter pylori infection as the cause of gastric carditis. Mod Pathol 1998, 11:950-956.
16. 16 Katzka DA, Gideon RM, Castell DO: Normal patterns of acid exposure at the gastric cardia: a functional midpoint between the esophagus and the stomach. Am J Gastroenterol 1998, 93:1236-1242.
17. 17 Goldblum JR, Peek RM, Vicari JJ, Easley K, Falk GW, Richter JE, Rice TW: Inflammation of the gastric cardia [letter]. Gastroenterology 1999, 116:228-229.
18. 18 Kuhn J, Toohil RJ, Ulualp SO, Kulpa J, Hofmann C, Arndorfer R, Shaker R: Pharyngeal acid reflux events in patients with vocal cord nodules. Laryngoscope 1998, 108:1146-1149.
19. 19 Blustein PK, Beck PL, Meddings JB, Van Rosendaal GM, Bailey RJ, Lalor E, et al.: The utility of endoscopy in the management of patients with gastroesophageal reflux disease. Am J Gastroenterol 1998, 93:2508-2512. The utility of endoscopy in the management of GERD is uncertain. This study of 742 patients examined the impact of endoscopy on subsequent therapy. Regardless of endoscopic findings, the most common management decision was to either switch to omeprazole or increase the dose of omeprazole in these patients. Empiric therapy with a proton pump inhibitor continues to show promise as the initial approach to the GERD patient presenting without complications.
20. 20 Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman AR, et al.: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997, 92:1997-2000.
21. 21 Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A: Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998, 42:13-16.
22. 22 Harris RA, Kuppermann M, Richter JE: Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997, 95:2179-2186.
23. 23 Diebold MD, Richardson S, Duchateau A, Bigard MA, Colin R, Cortot A, et al.: Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Dig Dis Sci 1998, 43:1629-1635.
24. 24 Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998, 93:763-767. This study is the initial description of nocturnal acid breakthrough, defined as recovery of gastric acid secretion lasting greater than 1 hour, in volunteers and GERD patients taking proton pump inhibitors twice daily. Nocturnal acid breakthrough occurred in 75% of the individuals studied within 12 hours of the evening dose of the proton pump inhibitor.
25. 25 Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998, 115:1335-1339. This double-blind, placebo-controlled, crossover study examined the effect of a third dose of omeprazole given at bedtime compared with ranitidine or placebo on nocturnal intragastric acid breakthrough in healthy volunteers receiving omeprazole (20 mg twice daily). The median time that intragastric pH was less than 4 was 48% for placebo, 31% for omeprazole (20 mg), 5% for ranitidine (150 mg), and 6% for ranitidine (300 mg). Thus, a nocturnal dose of ranitidine was superior to the more potent proton pump inhibitor in decreasing nocturnal intragastric pH. The observation is interesting, but the clinical relevance of this finding is unproven. It is hypothesized that nocturnal acid breakthrough may explain the inconsistent effects of proton pump inhibitors in atypical GERD.
26. 26 Levin TR, Sperling RM, McQuaid KR: Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. Am J Gastroenterol 1998, 93:1060-1063.
27. 27 Castell DO, Sigmund C, Patterson D, Lambert R, Hasner D, Clyde C, Zeldis JB: Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. Am J Gastroenterol 1998, 93:547-552.
28. 28 Viljakka M, Nevalainen J, Isolauri J: Lifetime costs of surgical versus medical treatment of severe gastroesophageal reflux disease in Finland. Scand J Gastroenterol 1997, 32:766-772.
29. 29 Peters JH, DeMeester TR, Crookes P, Oberg S, De Vos Shoop M, Hagen JA, Bremner CG: The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: prospective evaluation of 100 patients with "typical" symptoms. Ann Surg 1998, 228:40-50.
30. 30 Trus TL, Laycock WS, Wo JM, Waring JP, Branum GD, Mauren SJ, et al.: Laparoscopic antireflux surgery in the elderly. Am J Gastroenterol 1998, 93:351-353.
31. 31 Beckingham IJ, Cariem AK, Bornman PC, Callanan MD, Louw JA: Oesophageal dysmotility is not associated with poor outcome after laparoscopic Nissen fundoplication. Br J Surg 1998, 85:1290-1293. It is often recommended that fundoplication be avoided or modified in patients with abnormal esophageal motility. Not all groups agree with that approach, and this study demonstrated no difference in dysphagia at 1 year in 48 patients with normal motility and 33 patients with abnormal motility all of whom underwent the same operation, a 2-cm "floppy" Nissen fundoplication. Clearly, there is a need for more controlled data to support the common surgical belief that antireflux surgery should be tailored to esophageal physiology.
32. 32 Jobe BA, Wallace J, Hansen PD, Swanstrom LL: Evaluation of laparoscopic Toupet fundoplication as a primary repair for all patients with medically resistant gastroesophageal reflux. Surg Endosc 1997, 11:1080-1083.
33. 33 So JB, Zeitels SM, Rattner DW: Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery 1998, 124:28-32. The introduction of laparoscopic fundoplication has lowered the threshold for antireflux surgery. In this study, only 19 of 34 patients (56%) who underwent a laparoscopic fundoplication for atypical symptoms (cough, asthma, hoarseness, globus, chest pain) had symptom relief. These results are in marked contrast to the results of surgery for typical symptoms. The only preoperative predictors of a satisfactory outcome were a response of atypical symptoms to antisecretory therapy preoperatively and abnormal proximal acid exposure. This study emphasizes the importance of careful patient selection prior to antireflux surgery for patients with atypical symptoms.
34. 34 Kozarek RA, Low DE, Raltz SL: Complications associated with laparoscopic anti-reflux surgery: one multispecialty clinic's experience. Gastrointest Endosc 1997, 46:527-531.